Amgen Inc. (AMGN) Q1 2025 Earnings Results

Amgen Beats on EPS, Stock Down 2.45%

Amgen's earnings report shows a strong performance in EPS, exceeding expectations significantly. However, the stock reacted negatively, dropping 2.45% likely due to the lack of revenue details and guidance. Investors may be cautious as they await more information on future performance and strategic initiatives.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$4.90	N/A	+17.85%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed confidence in the company's strategic direction despite not providing specific guidance. They are focused on innovation and efficiency.

Management highlighted strong performance in key therapeutic areas.

They noted ongoing investments in R&D to drive future growth.

There was an emphasis on maintaining operational efficiency.

Amgen Beats on EPS, Stock Down 2.45%

Key numbers

Management commentary

Amgen Inc.

More earnings this week

Amgen Beats on EPS, Stock Down 2.45%

Key numbers

Management commentary